Table 1.
Patient characteristics
| Study label |
Gender | IGHV status1 |
Cytogenetic alterations2 |
ON 01910.Na LD50 (48h, μM)3 |
|---|---|---|---|---|
| CLL 1 | F | M | 11q del; 13q del | 0.96 |
| CLL 2 | F | M | 13q del | 1.48 |
| CLL 3 | M | U | 17p del | 0.48 |
| CLL 4 | M | M | trisomy 12 | 5.43 |
| CLL 5 | M | U | trisomy 12 | 0.97 |
| CLL 6 | M | U | nd | 1.08 |
| CLL 7 | M | M | 17p del; 11q del; 13q del | 0.78 |
| CLL 8 | F | M | 13q del | 0.55 |
| CLL 9 | F | U | 13q del | 0.78 |
| CLL 10 | F | M | 17p del; 13q del | 0.55 |
| CLL 11 | F | U | 13q del | 0.58 |
| CLL 12 | M | U | 11q del; 13q del | 1.18 |
| CLL 13 | M | M | 17p del | 0.90 |
| CLL 14 | F | M | 13q del | 0.52 |
| CLL 15 | M | U | 13q del | 1.67 |
| CLL 16 | F | U | 11q del;13q del | 0.52 |
| CLL 17 | F | U | 17p del;11q del;13q del | 1.59 |
| CLL 18 | M | U | 11q del; 13q del | 0.92 |
| CLL 19 | M | U | 11q del; 13q del | 1.06 |
| CLL 20 | M | U | 17p del | 0.43 |
| CLL 21 | F | U | 13q del | >8 |
| CLL 22 | M | M | 13q del | 0.2 |
| CLL 23 | F | U | 17p del | 3.20 |
| CLL 24 | M | M | 13q del | 1.94 |
| CLL 25 | M | U | normal | 4.15 |
| CLL 26 | F | U | 17p del | 0.21 |
| CLL 27 | M | U | 11q del | 0.88 |
| CLL 28 | M | U | 11q del | 1.19 |
| CLL 29 | M | U | 6q del | >8 |
| CLL 30 | M | U | 11q del; trisomy 12 | 0.8 |
| CLL 31 | M | U | 13q del | 0.95 |
| CLL 32 | M | U | 13q del | 1.10 |
| CLL 33 | M | U | 11q del | 0.55 |
| CLL 34 | M | U | normal | 1.24 |
1
IGHV sequence is considered mutated when its homology to the germline IGHV sequence is below 98%
2
Determined by interphase fluorescence in situ hybridization
3
Calculated by non linear regression using Prism 4 software